To elucidate the expression of the atrial natriuretic polypeptide (ANP) gene in the ventricle of the human failing heart, we have measured ANP and ANP messenger RNA (ANPmRNA) levels in left ventricular aneurysm obtained at operation, biopsy specimens of left ventricles from dilated cardiomyopathy (DCM) and autopsy samples of old myocardial infarction (OMI) and DCM hearts, and compared the levels with those in the normal ventricle. The ANP level (mean±SE) was 17.5±6.9 ng/g in the normal ventricle, and increased to 6603±122.2 ng/g in the left ventricular aneurysm tissues and to 3,138.6±1,642.1 ng/g in the biopsy specimens of the DCM ventricle. These levels were 40 and 200 times higher than in the normal ventricle. The increase of ANP levels was observed in both infarcted and noninfarcted regions of the OMI heart, and in the entire ventricle of the DCM heart. A significant positive correlation was found between the ANP level in aneurysm tissues and pulmonary capillary wedge pressure (r = 0.85). The ANPmRNA level in the left ventricular aneurysm showed about a 10-fold increase compared with that in the normal heart and reached 23% of that in the atrium of the same heart. A similar increase in the ANPmRNA level was observed in the entire ventricle of DCM. These data clearly indicate that the expression of the ANP gene in the ventricle is augmented in the failing heart in accordance with the severity of heart failure. In the atrium of the failing heart, ANP and ANPmRNA levels were only two times higher than those in the normal atrium. Thus, the augmentation in the expression of the ANP gene was more prominent in the ventricle than in the atrium. Taking tissue weight into account, the total content of ANPmRNA in the ventricle of the failing heart is much the same as that in the normal atrium. The ratio of the ANP level to the ANPmRNA level in the ventricle is much smaller than that in the atrium. These results suggest more rapid secretion of ANP after synthesis in the ventricle. These findings demonstrate that the expression of the ANP gene is augmented in the human ventricle of the failing heart and suggest that the ventricle becomes a substantial source of circulating ANP in congestive heart failure.
Introduction
To elucidate the expression of the atrial natriuretic polypeptide (ANP) gene in the ventricle of the human failing heart, we have measured ANP and ANP messenger RNA (ANPmRNA) levels in left ventricular aneurysm obtained at operation, biopsy specimens of left ventricles from dilated cardiomyopathy (DCM) and autopsy samples of old myocardial infarction (OMI) and DCM hearts, and compared the levels with those in the normal ventricle. The ANP level (mean±SE) was 17.5±6.9 ng/g in the normal ventricle, and increased to 6603±122.2 ng/g in the left ventricular aneurysm tissues and to 3,138.6±1,642.1 ng/g in the biopsy specimens of the DCM ventricle. These levels were 40 and 200 times higher than in the normal ventricle. The increase of ANP levels was observed in both infarcted and noninfarcted regions of the OMI heart, and in the entire ventricle of the DCM heart. A significant positive correlation was found between the ANP level in aneurysm tissues and pulmonary capillary wedge pressure (r = 0.85). The ANPmRNA level in the left ventricular aneurysm showed about a 10-fold increase compared with that in the normal heart and reached 23% of that in the atrium of the same heart. A similar increase in the ANPmRNA level was observed in the entire ventricle of DCM. These data clearly indicate that the expression of the ANP gene in the ventricle is augmented in the failing heart in accordance with the severity of heart failure. In the atrium of the failing heart, ANP and ANPmRNA levels were only two times higher than those in the normal atrium. Thus, the augmentation in the expression of the ANP gene was more prominent in the ventricle than in the atrium. Taking tissue weight into account, the total content of ANPmRNA in the ventricle of the failing heart is much the same as that in the normal atrium. The ratio of the ANP level to the ANPmRNA level in the ventricle is much smaller than that in the atrium. These results suggest more rapid secretion of ANP after synthesis in the ventricle.
These findings demonstrate that the expression of the ANP gene is augmented in the human ventricle of the failing heart and suggest that the ventricle becomes a substantial source of circulating ANP in congestive heart failure.
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Atrial natriuretic polypeptide (ANP)l is a cardiac hormone secreted through the coronary sinus from the heart and is involved in fluid, electrolyte, and vascular homeostasis (1) (2) (3) (4) (5) (6) (7) . The plasma ANP concentration is increased in patients with congestive heart failure (CHF) in relation to its severity (8) (9) (10) , and this elevation of the plasma ANP concentration is mainly due to increased secretion of ANP from the heart (7, 1 1). It is ofgreat importance, therefore, to investigate ANP synthesis in the human failing heart in order to elucidate the clinical implication ofANP in CHF. We have recently reported that ANP synthesis is augmented in the atrium in accordance with the severity of CHF (12). Since ANP was first discovered from atrial tissues, the atrium had been thought to be the sole source of circulating ANP (4, (13) (14) (15) (16) . There is growing evidence, however, indicating that ANP is also synthesized in the ventricle of normal animals (17-19) and that ANP synthesis in the ventricle is increased under certain pathological conditions, such as spontaneously hypertensive rats (SHR) (20, 21) , SHR stroke-prone (20) , cardiomyopathic hamsters (22) , experimentally volume or pressure overloaded rats (23) (24) (25) , and myocarditis mice (26). In evaluating ANP synthesis in the human failing heart, it is, therefore, necessary to investigate ANP synthesis not only in the atrium but also in the ventricle. To date, however, there has been only a few preliminary reports on human ventricular ANP. We reported that the ANP gene is expressed in the normal ventricle as well as in the atrium and that the expression is augmented in the ventricle in a patient with dilated cardiomyopathy (DCM) (27) . Immunohistochemical studies performed by us and others have also confirmed the increased ANP immunostaining in diseased ventricular cardiocytes (28, 29) .
Specimens obtained at operation and biopsy have a great advantage for the precise analysis of ANP and ANPmRNA levels, because of minimal postmortem nonspecific degradation. On the other hand, the autopsy sample is useful to evaluate ANP synthesis in the whole heart. To further elucidate ANP synthesis in the ventricle of the human failing heart, we investigated in the present study ANPmRNA (Fig. 2) . Small specimens (2-4 mg) were obtained at biopsy from the subendocardium of left ventricular free wall using biotorm (Machida Tokyo, Japan) in four patients with DCM. Atrial tissues were also obtained from the apical portion of the right auricle in six patients with left ventricular aneurysm and in five patients with CAD, when the venous cannula was inserted into the right auricle for the extracorporal circulation. Blocks were immediately frozen in liquid nitrogen and stored at -70'C until extraction. In the failing heart, the weight was significantly increased to 480±40 g. Ventricular hypertrophy was also evident by increases in the left and right ventricular wall thickness (16.0±2.3 and 6.7±1.3 mm, respectively). In patients without cardiac complications and in the patient with DCM, several ventricular tissues were dissected from both ventricles as shown in Fig. 1 and Fig. 4 . In patients with OMI, several blocks of ventricular tissues were also dissected from both infarcted and noninfarcted regions as illustrated in Fig. 3 . Atrial tissues (0.5-1.0 g) were dissected from apical and proximal portions of bilateral auricles and nonauricle parts of both atria. Blocks were immediately frozen and stored at -70'C until extraction.
Blood sampling. Blood samplings for the measurement of the plasma ANP concentration were performed from an antecubital vein a few days before the operation or within 1 wk before death, as previously reported (5, 6, 8) .
Extraction of total RNA and Northern blotting analysis. Cardiac tissues obtained at the operation or within 5 h after death were used for the analysis of tissue ANPmRNA. Biopsy specimens were not used for this purpose because of small sizes of specimens (2-4 mg). Total RNA was extracted from atrial and ventricular tissues in 4 M guanidium thiocyanate buffer and the ANPmRNA level was measured by Northern blot analysis, as previously reported (15, 20, 27) . A 32P-labeled 58 l-bp restriction fragment of the human ANP complementary DNA was prepared by the random-priming method (30) with [a-32P]dCTP (Amersham International, Buckinghamshire, UK), and was used as a probe. ANPmRNA levels (arbitrary units) per 1 ,ug of total RNA were expressed as relative levels to that in the apical portion of the right auricle obtained from patients with CAD and normal cardiac function (NYHA Functional Class I).
Extraction ofANPfrom tissues or plasma. Extraction of ANP from cardiac tissues was carried out as previously reported (4, 5, 12, 14, 31). Extraction of ANP from plasma was performed using a Sep-Pak C18 cartridge (Waters Associates Inc., Milford, MA) as previously reported (5, 6) .
RIA for ANP. Measurement of tissue and plasma ANP levels were performed using the specific RIA for ANP (5, 6, 14, 32) . This RIA recognizes the COOH-terminal portion of a-human ANP, a-human ANP (17-28). Cross-reactivities with #-human ANP and y-human ANP in the RIA were 120 and 100%, respectively, on a molar basis.
High performance gel permeation chromatography (HP-GPC). HP-GPC was performed on a TSK-GEL G2000 SW (Toyo Soda, Tokyo, Japan) column (7.5 X 600 mm), eluted with 10 mM trifluoroacetic acid containing 0.2 M sodium chloride and 30% acetonitrile as a solvent, as previously reported (7, 12, 14) .
Peptides. Results Plasma ANP concentrations. The plasma ANP concentration in patients with CHF ranged from 68.7 to 3,940.0 pg/ml with mean±SE of 690.0±283.7 (Tables I, II, and IV) , showing -20-fold increase in comparison with that in normal subjects (37.7±7.0 pg/ml) (5).
Tissue ANP levels and contents Normal heart. Tissue ANP levels in normal hearts are summarized in Fig. 1 (Table I) . When the aneurysm was divided into the endocardial and epicardial halves, the former contained higher amounts of ANP than the latter (1,016.4±152.1 vs. 167.2±37.8 ng/g). The ANP level in the aneurysm was 1.4±0.1 % ofthat in the atrium ofthe (Table II) . Failing heart (autopsy samples). Fig. 3 shows ANP levels in several regions of the heart in a representative patient with OMI (patient 1). Tissue ANP levels in infarcted and noninfarcted regions of the ventricle were 1,011.7±200.9 and 918.8±538.8 ng/g, respectively. The ANP level in the right ventricle was also increased to 125.4±50.4 ng/g. The remaining two patients with OMI also showed increased ANP levels in both infarcted and noninfarcted regions of the ventricle (Table IV) . The average ANP levels in the ventricle and atrium in these patients were 411.5±264.2 ng/g and 111.0±33.5 ,ug/g, respectively. Thus, the percentage of the ventricular to atrial ANP level was 0.31±0.09%. Total ANP content in the ventricle was 1.87±0.37% of that in the atrium, because ventricular weight was about six times heavier than atrial weight. The DCM heart also showed a 10-50-fold increase in ANP levels compared with normal hearts in various parts of the ventricle as shown in Fig. 4 . In the atrium, however, the average of ANP levels in DCM was only about two times higher than that of normal hearts (70.7 vs. 40.5±7.2 Mg/g). The ventricular ANP level was 1.4% of the atrial ANP level. The total ANP content in the DCM atrium and ventricle were 6,717 and 365 gg, respectively. The total ANP content in the DCM ventricle was 5.4% ofthat in the DCM atrium and was 21% ofthat in the normal atrium.
Northern blot analysis Normal heart. Northern blot analysis of RNA from the atrium and ventricle revealed that total RNA extracted from normal atrium and ventricle contained a hybridizing RNA band of -950 bp (Fig. 5) of the ANPmRNA level in the atrium of the same heart (Fig.  4) . The ANPmRNA level in the DCM atrium was two times higher than that in the normal atrium (1,800 mU/,gg RNA vs.
930 mU/pg RNA). The total ANPmRNA content in the DCM ventricle was 30% of that in the DCM atrium (9,500 U) and was comparable to that in the normal atrium (9,500 U vs. 7,300 U). Ratio of the ANP level to the ANPmRNA level (ANP/ ANPmRNA ratio). The ratios of ANP/ANPmRNA in normal and failing ventricles were 10-fold less than those in atria ofthe same hearts, as shown in Table V. HP-GPC profiles. To elucidate the molecular form of ANP in the atrium and ventricle of the failing heart, atrial and ventricular extracts from patients with left ventricular aneurysm and DCM (except one patient examined at autopsy) were analyzed by HP-GPC. a-Human ANP-like immunoreactivity (ahuman ANP-LI) applied to the HP-GPC column ranged from 2.0 to 9.9 ng, and total a-hANP-LI recovered in all HP-GPC fractions was 86.2±6.3% in atrial extracts and 70.2±8.2% in ventricular extracts. The predominant component of ahuman ANP-LI in each extract from the normal atrium and ventricle was y-human ANP. Fig. 6 shows HP-GPC profiles of extracts of the right atrium and aneurysm tissue of representative two patients with left ventricular aneurysm. In three of six patients with left ventricular aneurysm, the HP-GPC profile of extracts from the right auricle revealed that a-human ANP-LI consisted of a large molecular form, y-human ANP, and low molecular form(s), a-human ANP and/or #-human ANP. In the remaining three patients, only a-human ANP and/or f3- Results in the DCM heart were derived from those in the patient with DCM who was examined after death. In the calculation of V/A %, the value of V/A % in each patient was obtained and the mean value was calculated. (28, 29) . All these observations indicate that the expression of the ANP gene is increased in cardiomyocytes of the entire ventricle in the human failing heart. A positive correlation was found between the maximal ANP levels in ventricular aneurysm tissues and PCWP, suggesting that the ventricular ANP gene expression is increased with the severity ofCHF as is the case ofatrial ANP gene expression (12). It is noteworthy, however, that the percent increase of ANP and ANPmRNA levels in the ventricle is more prominent than that in the atrium of the failing heart. That is, two to three times increase ofthe ANP level was found in the DCM or OMI atrium compared with the normal atrium, whereas 40-50 times increase was found in the ventricle. In addition, the ANPmRNA level in the ventricle showed also 10 times increase in aneurysm or DCM tissues compared with normal ventricles. The ANP gene expression in the ventricle of the failing heart was more prominent in the endocardial than in the epicardial half.
In the present study, the DCM ventricle obtained at autopsy contained 7% of the ANPmRNA of the atrium in the concentration. The total ANPmRNA content in the DCM ventricle was 30% of that in the DCM atrium and was much the same as that in the normal atrium. Similarly, the ANPmRNA level in the ventricle with aneurysm reached 23% of that in the atrium of the same heart. Therefore, the total content ofANPmRNA in the failing ventricle is comparable to that in the normal atrium. These results suggest that the failing ventricle secretes a considerable amount of ANP and contributes to the elevation of the plasma ANP concentration in patients with CHF. Our unpublished observation demonstrates that the difference between the plasma ANP levels in the aorta and those in the interventricular vein draining the blood from the ventricle is much greater in patients with DCM than in control patients, indicating augmented secretion of ANP from the failing ventricle. In addition, we have recently reported that the total amount of ANPmRNA in the ventricle is about three times larger than that in the atrium in SHR-stroke prone (20) . It is possible, therefore, that the amount of ANP secreted from the ventricle may exceed that from the atrium in some patients with severe CHF.
In this study the plasma ANP concentration in patients with CHF was about 20 times higher than that in normal subjects. The data of ANPmRNA suggest that the total amount of ANPmRNA in the whole failing heart is increased by about three-to fourfold in comparison with that in the whole normal heart. Therefore,/these findings suggest that the increased expression of the ANP gene in the failing heart may not be sufficient to account for the elevation of the plasma ANP level in CHF, although the possibility that accelerated secretion and altered turnover of ANPmRNA in the failing heart cannot be ruled out. The discrepancy may be explained in part by decreased clearance of circulating ANP in CHF, which might relate to down regulation of ANP receptors in CHF (33) .
Simultaneous increases in ANPmRNA and ANP levels in the ventricle of the failing heart indicate that ANPmRNA is actually translated to ANP in the ventricle. However, the ANP/ANPmRNA ratio in the ventricle was smaller than that in the atrium in patients with OMI and DCM as well as in control subjects. A The gene expression of ANP in the ventricle has been reported to be increased in neonatal rats and decreased during the first week of life (18) . We have also reported that the ANP concentration in the ventricle is more than 1 4tg/g in human fetuses at 14 and 22 wk gestation, that it decreases in parallel with fetal development, and that adult ventricle contains < 50 ng/g of ANP (35) . These results indicate that the expression of the ANP gene is reinduced in the ventricle of patients with CHF. It is well documented that contractile protein isoforms are reinduced in human and animal hearts under various pathological conditions (25, (36) (37) (38) (39) . The mechanism responsible for the reinduction of the ANP gene in the failing ventricle is not clear at present. The aortic ligation and aortovenous fistula were reported to cause the augmented expression of the ANP gene in the rat ventricle in association with ventricular hypertrophy (23) (24) (25) . In addition, the expression of the ANP gene is markedly increased in ventricles of SHR and SHRstroke prone at the stage of established hypertension and ventricular hypertrophy (20, 21) . In the present study, concomitant increases in the ANP gene expression and ventricular mass were observed in patients with OMI and DCM, and a positive significant correlation was found between PCWP, or left ventricular end-diastolic pressure, and the maximal ANP level in the left ventricular aneurysm. All these results suggest that ventricular hypertrophy and the augmented expression of the ANP gene in the ventricle may be induced by the common mechanism and that ventricular stretch due to an increase in after-or preload on the ventricle leads to the reinduction ofthe ANP gene. The observation that an endocardial half of the ventricle contained more ANP than an epicardial half also supports the concept of stretch induced reinduction of the ANP gene, because the wall tension in the endocardial half is greater than that in the epicardial half (40) . Further studies are necessary to clarify the precise mechanism of the augmented expression of the ANP gene in the ventricle, and the relationship between the augmented expression of the ANP gene and ventricular hypertrophy.
What is the significance ofthe augmented expression ofthe ANP gene in the ventricle? Since the intravenous infusion of ANP improves left ventricular function in CHF, we have proposed that augmented ANP synthesis in the atrium is a compensatory mechanism (8, 41, 42) .2 The present study further indicates that the ventricle also possesses the self-compensatory mechanism, an increase of ANP secretion, like autoregulation (Frank-Starling law of the heart) and hypertrophy (43) .
